Oncology NEWS International Vol 14 No 4

Novel Prostate Cancer Vaccine Shows Survival Benefit

April 01, 2005

ORLANDO-A novel therapeutic vaccine therapy (see illustration) increased survival in patients with advanced prostate cancer during a phase III clinical trial, lead investigator Eric J. Small, MD, reported in an oral presentation and a media briefing at the 2005 Multidisciplinary Prostate Cancer Symposium (abstract 264). "This immunotherapy has the potential to provide a new treatment option for a group of patients with precious few options," said Dr. Small, professor of medicine and urology, University of California, San Francisco, School of Medicine. "On a broader scale, this is the first study ever to show a survival advantage for the immune approach in prostate cancer."

Exemestane Reduces the Risk of Breast Cancer Recurrence

April 01, 2005

SAN ANTONIO-Updated results from the Intergroup Exemestane Study of 4,740 breast cancer patients show adjuvant therapy with the aromatase inhibitor exemestane (Aromasin) after 2 to 3 years of tamoxifen can cut risk of recurrence by

Temodar Approved for Treating GBM in Combination With Radiotherapy

April 01, 2005

ROCKVILLE, Maryland-The Food and Drug Administration (FDA) has approved a new indication for Temodar capsules (temozolomide, Schering-Plough) for use concurrently with radiotherapy for the treatment of adults with newly diagnosed glioblastoma multiforme (GBM) and as maintenance therapy after radiotherapy. The FDA based its decision on study data that showed a statistically significant overall survival benefit in such patients.

PSA Velocity Predicts Prostate Ca Outcome

April 01, 2005

ORLANDO-Higher baseline PSA and rapid PSA doubling time (PSADT) are adversely associated with bone metastasis and death in patients with castrate nonmetastatic prostate cancer, according to a study presented at the 2005